Plasma levels of heat shock protein 90 alpha associated with lung cancer development and treatment responses

Clinical Cancer Research

Volumn 20, Issue 23, 2014, Pages 6016-6022

  Shi, Yuankai ^a   Liu, Xiaoqing ^b   Lou, Jiatao ^c   Han, Xiaohong ^a   Zhang, Lijian ^d   Wang, Qingtao ^e   Li, Baolan ^f   Dong, Mei ^g   Zhang, Yinghong ^h  

^a CANCER HOSPITAL   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

^d PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^e CAPITAL MEDICAL UNIVERSITY   (China)

^f CAPITAL MEDICAL UNIVERSITY   (China)

^g 309TH HOSPITAL OF PLA   (China)

^h XIAMEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 ALPHA; PACLITAXEL; PLACEBO; RECOMBINANT ENDOSTATIN; UNCLASSIFIED DRUG; HSP90ALPHA PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CARCINOGENESIS; CLINICAL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; CASE CONTROL STUDY; CLINICAL TRIAL; LUNG NEOPLASMS; MULTIMODALITY CANCER THERAPY; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; TREATMENT OUTCOME;

CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; COMBINED MODALITY THERAPY; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; ROC CURVE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84918515119     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0174     Document Type: Article

References (25)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. American Cancer Society. Cancer facts and figures. Atlanta, GA: American Cancer Society; 2009.
3. Chen W, Zheng R, Zhang S, Zhao P, Zeng H, Zou X, et al. Annual report on status of cancer in China, 2010. Chin J Cancer Res 2014;26:48-58.
4. Shi Y, Zhang L, Liu X, Zhou C, Zhang L, Zhang S, et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol 2013;14:953-61.
5. Pass HI, Beer DG, Joseph S, Massion P. Biomarkers and molecular testing for early detection, diagnosis, and therapeutic prediction of lung cancer. Thorac Surg Clin 2013;23:211-24.
6. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005;5:761-72.
7. Shames DS, Minna JD. IP6K2 is a client for HSP90 and a target for cancer therapeutics development. Proc Natl Acad Sci U S A 2008;105:1389-90.
8. Passarino G, Cavalleri GL, Stecconi R. Molecular variation of human hsp90a and hsp90beta genes in Caucasians. Hum Mutat 2003;21:554-5.
9. Eustace BK, Sakurai T, Stewart JK, Yimlamai D, Unger C, Zehetmeier C, et al. Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat Cell Biol 2004;6:507-14.
10. Wang XF, Song XM, Zhuo W, Fu Y, Shi H, Liang Y, et al. The regulatory mechanism of Hsp90 alpha secretion and its function in tumor malignancy. Proc Natl Acad Sci U S A 2009;160:21288-93.
11. Song X, Wang X, Zhuo W, Shi H, Feng D, Sun Y, et al. The regulatory mechanism of extracellular Hsp90α on matrix metalloproteinase-2 (MMP-2) processing and tumor angiogenesis. J Biol Chem 2010;285:40039-49
12. Sims JD, McCready J, Jay DG. Extracellular heat shock protein (Hsp)70 and Hsp90alpha assist in matrix metalloproteinase-2 activation and breast cancer cell migration and invasion. PLoS ONE 2011;6:e18848.
13. Pearl LH, Prodromou C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem 2006;75:271-94.
14. Sahu D, Zhao Z, Tsen F, Cheng CF, Park R, Situ AJ, et al. A potentially common peptide target in secreted heat shock protein-90alpha for hypoxia-inducible factor-1alpha-positive tumors. Mol Biol Cell 2012;23:602-13.
15. Wang Q, Sun W, Hao X, Li T, Su L, Liu X. Down-regulation of cellular FLICE-inhibitory protein (long form) contributes to apoptosis induced by Hsp90 inhibition in human lung cancer cells. Cancer Cell Int 2012;12:54.
16. Ostroff RM, Bigbee WL, Franklin W, Gold L, Mehan M, Miller YE, et al. Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. PLoS One 2010;5:e15003.
17. Garon EB, Finn RS, Hamidi H, Dering J, Pitts S, Kamranpour N, et al. The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth. Mol Cancer Ther 2013;12:890-900.
18. Shimamura T, Perera SA, Foley KP, Sang J, Rodig SJ, Inoue T, et al. Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Clin Cancer Res 2012;18:4973-85
19. Xiao W, Pacyna-Gengelbach M, Schluns K, An Q, Gao Y, Cheng S, et al. Differentially expressed genes associated with human lung cancer. Oncol Rep 2005;14:229-34.
20. Li W, Li Y, Guan S, Fan J, Cheng CF, Bright AM, et al. Extracellular heat shock protein-90alpha: linking hypoxia to skin cell motility and wound healing. EMBO J 2007;26:1221-33.
21. Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, Gaarenstroom K, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem 2010;56:e1-48.
22. Cabrera-Alarcon JL, Carrillo-Vico A, Santotoribio JD, Leon-Justel A, Sanchez-Gil R, Gonzalez-Castro A, et al. CYFRA 21-1 as a tool for distant metastasis detection in lung cancer. Clin Lab 2011;57:1011-4.
23. Alkotyfan K, Wiegand S, Muller HH, Windfuhr JP, Werner JA, Sesterhenn AM. Cyfra 21-1 as a tumor marker for follow-up of patients with squamous cell carcinoma of the oropharynx. Anticancer Res 2010;30:2291-6.
24. Chu XY, Hou XB, Song WA, Xue ZQ, Wang B, Zhang LB. Diagnostic values of SCC, CEA, Cyfra21-1 and NSE for lung cancer in patients with suspicious pulmonary masses: a single center analysis. Cancer Biol Ther 2011;11:995-1000.
25. Grunnet M, Sorensen JB. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer 2012;76:138-43.